Bioforce Nanosciences Holdings annual return on equity
2018
2019
Bioforce Nanosciences Holdings Return on Equity (ROE) Growth & History (BFNH)
Bioforce Nanosciences Holdings's return on equity was −120.70% for fiscal 2019.
View full Bioforce Nanosciences Holdings company overviewBioforce Nanosciences Holdings annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2019 | 2019-12-31 | −120.70% | +235.76 pp |
| 2018 | 2018-12-31 | −356.46% | — |
Bioforce Nanosciences Holdings quarterly return on equity
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 30.17% | — |
| Q1 2020 | 2020-03-31 | −578,937.88% | −578897.72 pp |
| Q4 2019 | 2019-12-31 | −42.17% | −10.19 pp |
| Q3 2019 | 2019-09-30 | −14.03% | +27.31 pp |
| Q2 2019 | 2019-06-30 | −18.87% | — |
| Q1 2019 | 2019-03-31 | −40.16% | — |
| Q4 2018 | 2018-12-31 | −31.98% | — |
| Q3 2018 | 2018-09-30 | −41.34% | — |
Bioforce Nanosciences Holdings return on equity trends
Between the periods ended 2018-12-31 and 2019-12-31, Bioforce Nanosciences Holdings's return on equity increased from −356.46% to −120.70%, a change of +235.76 percentage points. The latest reported quarter, Q2 2026, shows 30.17%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bioforce Nanosciences Holdings source filings ↗